PL
ZVRA icon

Parkwood LLC’s Zevra Therapeutics ZVRA Stock Holding History

Parkwood LLC’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,863
Closed -$503K – 393
2017
Q2 		$503K Hold
7,863
– – 0.08% 182
2017
Q1 		$616K Hold
7,863
– – 0.09% 158
2016
Q4 		$371K Hold
7,863
– – 0.06% 249
2016
Q3 		$565K Buy
7,863
+6,187
+369% +$440K 0.08% 176
2016
Q2 		$107K Buy
+1,676
New +$276K 0.02% 443

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Parkwood LLC's ZVRA Position: Q3 2017 in Review

Parkwood LLC sold out of Zevra Therapeutics (ZVRA) in Q3 2017, closing a stake of 7,863 shares — an estimated $503K sold.

Parkwood LLC first reported a position in ZVRA in Q2 2016 and held it in 5 quarters. The position peaked at $616K in Q1 2017. 26 funds tracked by Wall St. Rank hold ZVRA as of Q3 2017.

  • Parkwood LLC reported no remaining Zevra Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Parkwood LLC sold 7,863 Zevra Therapeutics shares in Q3 2017, an estimated $503K.
  • Parkwood LLC first reported a position in Zevra Therapeutics in Q2 2016 and held it in 5 quarters.
  • Parkwood LLC's Zevra Therapeutics position peaked at $616K in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2017.

Based on Parkwood LLC's 13F filing for Q3 2017, filed 1 Nov 2017.